Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.03
+$0.02 · +1.98%
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Previous close
$1.03
+$0.02 · +1.98%
Regular session · ET · Market data may be delayed.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Day range
Current $1.03
52-week range
Current $1.03
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
50
Fair Value
Sentiment
67
Bullish
Risk
65
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Day range
Current $1.03
52-week range
Current $1.03
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 4.62M USD | 3.64M USD | 6.33M USD | 7.01M USD | 8.89M USD |
| Gross profit | −4.62M USD | −3.64M USD | −6.33M USD | −7.01M USD | −8.89M USD |
| Research and development | 4.62M USD | 3.64M USD | 6.33M USD | 7.01M USD | 8.89M USD |
| Selling, general, and administrative | 4.6M USD | 3.74M USD | 4.29M USD | 4.45M USD | 4.63M USD |
| Operating expenses | 4.6M USD | 3.74M USD | 4.49M USD | 4.45M USD | 4.63M USD |
| Interest income | — | 231K USD | — | — | — |
| Depreciation and amortization | 3K USD | 2K USD | 184K USD | 71K USD | 75K USD |
| Operating income | −9.22M USD | −7.39M USD | −10.82M USD | −11.46M USD | −13.51M USD |
| Net income | −8.7M USD | −7.15M USD | −10.83M USD | −11.48M USD | −13.29M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
